Abstract: BAG-1 Genetic Polymorphisms Predict Clinical Responses to Platinum-Based Chemotherapyin Advanced Non-Small Cell Lung CancerYadiWANG, Jian CHENG, Junchen CHEN, YueWANG,Wei LIU, Minwen HACorrespondence to: Minwen HA, E-mail: hamw2002@yahoo.com.cnDepartment of Oncology, The First Affiliated Hospital of Liaoning Medical University, Jinzhou 121001, ChinaThis study was supported by a grant from the Scientific Research Project of Liaoning Provincial Educational Office (Grant no.L2010286)Abstract Objective: To examine the association between genetic polymorphisms of BAG-1 and the clinical response to plati-num-based chemotherapy for advanced non-small cell lung cancer ( NSCLC ). Methods: In total, 142 patients with advanced NSCLCwere routinely treated with paclitaxel/cisplatin or vinorelbine/cisplatin chemotherapy, and their clinical response was evaluated after 3cycles. The codon 324 of BAG-1 was genotyped by polymerase chain reaction-restrictive fragment length polymorphism using DNAsamples isolated from peripheral blood collected before treatment in 142 patients with advanced NSCLC. An unconditional logistic re-gression model was used to analyze the association between genetic polymorphisms and clinical response. Results: Of the 142 patients,the frequencies of BAG-1 codon324 C/C, C/T, and T/T genotypes were 77.46% ( 110/142 ), 22.54% ( 32/142 ), and 0, respectively. Theoverall chemotherapeutic response rate ( CR + PR ) among the patients was 32.39%, including 4 CR, 42 PR, 55 SD, and 41 PD. The re-sponse rate to chemotherapy was significantly higher in patients with the C/C genotype of the BAG-1 codon 324 allele than in patientswith the C/T genotype ( adjusted OR = 2.852; 95% CI: 1.133-7.182, P = 0.026 ). There was a significant difference in the progres-sion-free survival between patients with the C/C and C/T genotypes in BAG-1 codon324 ( 5.7 months vs. 5.3 months, P = 0.002 ). Simi-larly, overall survival was better among patients with the C/C genotype than those with the C/T genotype ( 8.1 months vs. 7.7 months,P = 0.013 ). Cox multivariate analysis showed that codon 324 of BAG-1 with the C/T genotype is associated with a higher risk of pro-gression in NSCLC patients compared with the C/C genotype ( P = 0. 002 ). Conclusion: Genetic polymorphisms in the codon 324 ofBAG-1 may have significant effects on the clinical response of NSCLC patients receiving platinum-based chemotherapy and those withthe C/T genotype may have poor prognosis.Keywords BAG-1; Non-small cell lung cancer; Genetic polymorphism